Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma.
OBJECTIVE
Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in many cancer and is emerging as a potential therapeutic target. Yet data on the expression of eIF4E in endometrial cancer are lacking.


METHODS
Immunohistochemistry was used to evaluate the expression of eIF4E in 62 endometrial cancer surgical specimens. We subsequently evaluated whether inhibition of eIF4E by siRNA would have an impact on cell growth in endometrial cancer cell lines, using the MTT cell proliferation assay.


RESULTS
According to a chosen cutoff value, 36 (58.1%) of 62 patient specimens scored as eIF4E positive. The positivity of eIF4E was significantly more frequent in tumors extending outside the uterus (stage III/IV vs. stage I/II, P = 0.027). Lastly, downregulation of eIF4E by siRNA reduced the growth of HEC-1A cells significantly but had a somewhat weaker effect in Ishikawa cells (P < 0.001).


CONCLUSIONS
Expressions of eIF4E correlated with prognosis of endometrial adenocarcinomas. Our results suggest that eIF4E might be a promising therapeutic target in endometrial cancer.
Choi
Chel Hun
CH
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-Gu, Seoul, 135-710, Korea.
Lee
Ji-Soo
JS
Kim
Seong Rim
SR
Lee
Yoo-Young
YY
Kim
Chul-Jung
CJ
Lee
Jeong-Won
JW
Kim
Tae-Joong
TJ
Lee
Je-Ho
JH
Kim
Byoung-Gie
BG
Bae
Duk-Soo
DS
D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D015536:Down-Regulation; D016889:Endometrial Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D039561:Eukaryotic Initiation Factor-4E / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D014162:Transfection
D039561:Eukaryotic Initiation Factor-4E; D034741:RNA, Small Interfering
J Cancer Res Clin Oncol. 2009 Jul;135(7):933-41
19107520
Mol Cancer Ther. 2008 Jul;7(7):1782-8
18644990
Gynecol Oncol. 2004 Mar;92(3):744-51
14984936
Cancer Treat Rev. 2007 Apr;33(2):177-90
17196749
Curr Opin Investig Drugs. 2002 Feb;3(2):295-304
12020063
Mol Cancer Ther. 2002 Sep;1(11):971-9
12481419
Br J Cancer. 1998 Jun;77(12):2120-8
9649123
Nat Rev Cancer. 2006 Sep;6(9):729-34
16915295
Am J Surg Pathol. 2002 Mar;26(3):312-9
11859202
Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):663-6
11401917
Oncogene. 2004 Apr 19;23(18):3189-99
15094768
Ann Surg. 2006 May;243(5):684-90; discussion 691-2
16633004
J Clin Oncol. 2006 Jan 1;24(1):36-44
16330675
Eur J Biochem. 2002 Nov;269(22):5350-9
12423333
Oncol Rep. 2008 Dec;20(6):1409-17
19020722
Cancer. 1997 Jun 15;79(12):2385-90
9191527
Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56
16436330
Ann Surg. 1998 May;227(5):756-6l; discussion 761-3
9605667
Ann Surg. 2002 May;235(5):732-8; discussion 738-9
11981220
Gynecol Oncol. 1991 Jan;40(1):55-65
1989916
Curr Opin Obstet Gynecol. 2002 Feb;14(1):59-65
11801878
Clin Exp Metastasis. 2003;20(3):265-73
12741684
J Clin Invest. 2007 Sep;117(9):2638-48
17786246